FDA Guidance Signals Clear Support for Efforts to Increase Trial Diversity
February 2, 2021
As part of its ongoing efforts to make clinical trials more representative of the population, the FDA issued a final guidance in November 2020 on what sponsors should do to make trials more accessible and appealing to under-represented racial, ethnic, gender and age groups.